Katia Falasca
Overview
Explore the profile of Katia Falasca including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
810
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fois M, De Vito A, Cherchi F, Ricci E, Pontolillo M, Falasca K, et al.
Antibiotics (Basel)
. 2024 Jul;
13(7).
PMID: 39061297
Hospital-acquired pneumonia (HAP) and ventilation-associated pneumonia (VAP) are challenging clinical conditions due to the challenging tissue penetrability of the lung. This study aims to evaluate the potential role of fosfomycin...
2.
Falasca K, Ucciferri C, Di Gasbarro A, Borrelli P, Di Nicola M, Frisenda C, et al.
BMC Infect Dis
. 2024 Jul;
24(1):665.
PMID: 38961336
To minimize the toxicity and impact of combined antiretroviral therapy (cART) on the lifestyle of people living with Human Immunodeficiency Virus (PLWH), scientific community evaluated the efficacy, safety and sustained...
3.
Falasca K, Vetrugno L, Borrelli P, Di Nicola M, Ucciferri C, Gambi A, et al.
Front Med (Lausanne)
. 2024 May;
11:1355144.
PMID: 38813381
Introduction: Coronavirus disease 2019 (COVID-19) is a highly contagious viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has had a dramatic effect on the world, resulting...
4.
Corti N, Menzaghi B, Orofino G, Guastavigna M, Lagi F, Di Biagio A, et al.
Viruses
. 2024 Apr;
16(4).
PMID: 38675955
Cardiovascular disease (CVD) is common in people with HIV (PWH), and has great impact in terms of morbidity and mortality. Several intertwined mechanisms are believed to play a role in...
5.
Tana C, Moffa L, Falasca K, Vecchiet J, Tana M, Mantini C, et al.
Ann Med
. 2023 Oct;
55(2):2265298.
PMID: 37839411
COVID-19 continues to present challenges in the care of older adults with frailty and/or comorbidities and very old patients, who can be hospitalized with severe COVID-19 despite full vaccination. Frailty...
6.
Squillace N, Ricci E, Maggi P, Taramasso L, Menzaghi B, De Socio G, et al.
PLoS One
. 2023 Aug;
18(8):e0289132.
PMID: 37556481
Introduction: Integrase strand transfer inhibitors (INSTI) are one of the most prescribed drug classes for the treatment of HIV infection worldwide. Emtricitabine/Tenofovir Alafenamide/ Bictegravir (FTC/TAF/BIC) has been evaluated in randomized...
7.
Maggi P, Ricci E, Martinelli C, De Socio G, Squillace N, Molteni C, et al.
Viruses
. 2023 Jul;
15(7).
PMID: 37515298
Doravirine (DOR) is a newly approved non-nucleoside reverse transcriptase inhibitor (NNRTI). We aimed to investigate, in a real-life setting, how switching to a DOR-based regimen rather than a rilpivirine (RPV)-based...
8.
Maggi P, Ricci E, Cicalini S, Pellicano G, Celesia B, Vichi F, et al.
BMC Infect Dis
. 2023 Apr;
23(1):227.
PMID: 37059996
Background: Doravirine (DOR) is a newly approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors (NNRTI), well tolerated and leading to an improved lipid profile in antiretroviral experienced...
9.
De Vito A, Ricci E, Menzaghi B, Orofino G, Martinelli C, Squillace N, et al.
Viruses
. 2023 Mar;
15(3).
PMID: 36992429
In the last years, many antiretroviral drugs (ART) have been developed with increased efficacy. Nowadays, the main reasons for treatment switches are adverse events, proactive strategy or simplification. We conducted...
10.
Taramasso L, Squillace N, Ricci E, Menzaghi B, Orofino G, De Socio G, et al.
AIDS
. 2023 Mar;
37(8):1269-1276.
PMID: 36927963
Objective: Recent reports of excessive weight gain in people with HIV (PWH) have raised increasing concerns on the possible increase of diabetes mellitus (DM) risk in course of integrase inhibitors...